214 related articles for article (PubMed ID: 21220498)
21. Prolonged extracellular signal-regulated kinase 1/2 activation during fibroblast growth factor 1- or heregulin beta1-induced antiestrogen-resistant growth of breast cancer cells is resistant to mitogen-activated protein/extracellular regulated kinase kinase inhibitors.
Thottassery JV; Sun Y; Westbrook L; Rentz SS; Manuvakhova M; Qu Z; Samuel S; Upshaw R; Cunningham A; Kern FG
Cancer Res; 2004 Jul; 64(13):4637-47. PubMed ID: 15231676
[TBL] [Abstract][Full Text] [Related]
22. Disruption of MEK/ERK/c-Myc signaling radiosensitizes prostate cancer cells in vitro and in vivo.
Ciccarelli C; Di Rocco A; Gravina GL; Mauro A; Festuccia C; Del Fattore A; Berardinelli P; De Felice F; Musio D; Bouché M; Tombolini V; Zani BM; Marampon F
J Cancer Res Clin Oncol; 2018 Sep; 144(9):1685-1699. PubMed ID: 29959569
[TBL] [Abstract][Full Text] [Related]
23. MEK inhibition induces MYOG and remodels super-enhancers in RAS-driven rhabdomyosarcoma.
Yohe ME; Gryder BE; Shern JF; Song YK; Chou HC; Sindiri S; Mendoza A; Patidar R; Zhang X; Guha R; Butcher D; Isanogle KA; Robinson CM; Luo X; Chen JQ; Walton A; Awasthi P; Edmondson EF; Difilippantonio S; Wei JS; Zhao K; Ferrer M; Thomas CJ; Khan J
Sci Transl Med; 2018 Jul; 10(448):. PubMed ID: 29973406
[TBL] [Abstract][Full Text] [Related]
24. Potentiation of the antitumor effects of both selective cyclooxygenase-1 and cyclooxygenase-2 inhibitors in human hepatic cancer cells by inhibition of the MEK/ERK pathway.
Cusimano A; Foderà D; D'Alessandro N; Lampiasi N; Azzolina A; Montalto G; Cervello M
Cancer Biol Ther; 2007 Sep; 6(9):1461-8. PubMed ID: 18424914
[TBL] [Abstract][Full Text] [Related]
25. Inhibition of MEK/ERK 1/2 pathway reduces pro-inflammatory cytokine interleukin-1 expression in focal cerebral ischemia.
Wang ZQ; Wu DC; Huang FP; Yang GY
Brain Res; 2004 Jan; 996(1):55-66. PubMed ID: 14670631
[TBL] [Abstract][Full Text] [Related]
26. Inhibition of either phosphatidylinositol 3-kinase/Akt or the mitogen/extracellular-regulated kinase, MEK/ERK, signaling pathways suppress growth of breast cancer cell lines, but MEK/ERK signaling is critical for cell survival.
Ripple MO; Kalmadi S; Eastman A
Breast Cancer Res Treat; 2005 Sep; 93(2):177-88. PubMed ID: 16187238
[TBL] [Abstract][Full Text] [Related]
27. The combination of rapamycin and MAPK inhibitors enhances the growth inhibitory effect on Nara-H cells.
Nakamura O; Hitora T; Yamagami Y; Mori M; Nishimura H; Horie R; Yamaguchi K; Yamamoto T
Int J Mol Med; 2014 Jun; 33(6):1491-7. PubMed ID: 24676456
[TBL] [Abstract][Full Text] [Related]
28. Identification of a novel inhibitor of mitogen-activated protein kinase kinase.
Favata MF; Horiuchi KY; Manos EJ; Daulerio AJ; Stradley DA; Feeser WS; Van Dyk DE; Pitts WJ; Earl RA; Hobbs F; Copeland RA; Magolda RL; Scherle PA; Trzaskos JM
J Biol Chem; 1998 Jul; 273(29):18623-32. PubMed ID: 9660836
[TBL] [Abstract][Full Text] [Related]
29. U0126 prevents ERK pathway phosphorylation and interleukin-1beta mRNA production after cerebral ischemia.
Wang ZQ; Chen XC; Yang GY; Zhou LF
Chin Med Sci J; 2004 Dec; 19(4):270-5. PubMed ID: 15669185
[TBL] [Abstract][Full Text] [Related]
30. Inhibition of CD3/CD28-mediated activation of the MEK/ERK signaling pathway represses replication of X4 but not R5 human immunodeficiency virus type 1 in peripheral blood CD4(+) T lymphocytes.
Popik W; Pitha PM
J Virol; 2000 Mar; 74(6):2558-66. PubMed ID: 10684270
[TBL] [Abstract][Full Text] [Related]
31. c-Myc Sustains Transformed Phenotype and Promotes Radioresistance of Embryonal Rhabdomyosarcoma Cell Lines.
Gravina GL; Festuccia C; Popov VM; Di Rocco A; Colapietro A; Sanità P; Monache SD; Musio D; De Felice F; Di Cesare E; Tombolini V; Marampon F
Radiat Res; 2016 Apr; 185(4):411-22. PubMed ID: 27104757
[TBL] [Abstract][Full Text] [Related]
32. MEK inhibition enhances paclitaxel-induced tumor apoptosis.
MacKeigan JP; Collins TS; Ting JP
J Biol Chem; 2000 Dec; 275(50):38953-6. PubMed ID: 11038347
[TBL] [Abstract][Full Text] [Related]
33. Multiple anticancer effects of blocking MEK-ERK signaling in hepatocellular carcinoma.
Wiesenauer CA; Yip-Schneider MT; Wang Y; Schmidt CM
J Am Coll Surg; 2004 Mar; 198(3):410-21. PubMed ID: 14992744
[TBL] [Abstract][Full Text] [Related]
34. Pharmacological targeting of the ephrin receptor kinase signalling by GLPG1790 in vitro and in vivo reverts oncophenotype, induces myogenic differentiation and radiosensitizes embryonal rhabdomyosarcoma cells.
Megiorni F; Gravina GL; Camero S; Ceccarelli S; Del Fattore A; Desiderio V; Papaccio F; McDowell HP; Shukla R; Pizzuti A; Beirinckx F; Pujuguet P; Saniere L; der Aar EV; Maggio R; De Felice F; Marchese C; Dominici C; Tombolini V; Festuccia C; Marampon F
J Hematol Oncol; 2017 Oct; 10(1):161. PubMed ID: 28985758
[TBL] [Abstract][Full Text] [Related]
35. Aryl hydrocarbon receptor activation and cytochrome P450 1A induction by the mitogen-activated protein kinase inhibitor U0126 in hepatocytes.
Andrieux L; Langouët S; Fautrel A; Ezan F; Krauser JA; Savouret JF; Guengerich FP; Baffet G; Guillouzo A
Mol Pharmacol; 2004 Apr; 65(4):934-43. PubMed ID: 15044623
[TBL] [Abstract][Full Text] [Related]
36. Crosstalk between the PI3K/mTOR and MEK/ERK pathways involved in the maintenance of self-renewal and tumorigenicity of glioblastoma stem-like cells.
Sunayama J; Matsuda K; Sato A; Tachibana K; Suzuki K; Narita Y; Shibui S; Sakurada K; Kayama T; Tomiyama A; Kitanaka C
Stem Cells; 2010 Nov; 28(11):1930-9. PubMed ID: 20857497
[TBL] [Abstract][Full Text] [Related]
37. Glucose dependence of glycogen synthase activity regulation by GSK3 and MEK/ERK inhibitors and angiotensin-(1-7) action on these pathways in cultured human myotubes.
Montori-Grau M; Tarrats N; Osorio-Conles O; Orozco A; Serrano-Marco L; Vázquez-Carrera M; Gómez-Foix AM
Cell Signal; 2013 May; 25(5):1318-27. PubMed ID: 23453973
[TBL] [Abstract][Full Text] [Related]
38. Dual targeting of PI3K and MEK enhances the radiation response of K-RAS mutated non-small cell lung cancer.
Toulany M; Iida M; Keinath S; Iyi FF; Mueck K; Fehrenbacher B; Mansour WY; Schaller M; Wheeler DL; Rodemann HP
Oncotarget; 2016 Jul; 7(28):43746-43761. PubMed ID: 27248324
[TBL] [Abstract][Full Text] [Related]
39. Activation of Akt1 by human 5-hydroxytryptamine (serotonin)1B receptors is sensitive to inhibitors of MEK.
Hsu EH; Lochan AC; Cowen DS
J Pharmacol Exp Ther; 2001 Aug; 298(2):825-32. PubMed ID: 11454948
[TBL] [Abstract][Full Text] [Related]
40. RNAi-mediated ERK2 knockdown inhibits growth of tumor cells in vitro and in vivo.
Bessard A; Frémin C; Ezan F; Fautrel A; Gailhouste L; Baffet G
Oncogene; 2008 Sep; 27(40):5315-25. PubMed ID: 18521085
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
